TEVA250103C19000
- 2.50
- -0.30-10.71%
Teva Pharmaceutical Industries Newsroom
Novo Nordisk Seeks to Block Compounded Victoza
Insider Trades: Walmart, Teva Among Notable Names This Week
Teva Pharmaceutical Industries Ltd (TEVA) Ends Trading Week Defying Market Bloodbath
Teva Pharmaceutical Industries(TEVA.US) Director Sells US$6.29 Million in Common Stock
Teva Pharmaceutical on Track for Highest Close Since November 2018 -- Data Talk
TEVA Stock Soars to 52-week High, Reaches $22.52
Tesla, Avinger, Jet.Ai, Teva, And Netflix: Why These 5 Stocks Are On Investors' Radars Ahead Of Christmas
Teva Pharmaceutical Shares Surged for Seven Straight Sessions
FDA Approves First Generic of Novo Nordisk's Victoza
Teva to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More
Teva Pharmaceutical, Li Auto, And Darden Restaurants Are Among Top Large Cap Gainers Last Week (December 16-20): Are The Others In Your Portfolio?
Trending Stocks in Bearish Pre-holiday Week for U.S. Stock Market
Teva Pharmaceutical Industries Limited (TEVA): A Bull Case Theory
Express News | Form 144 | Teva Pharmaceutical Industries(TEVA.US) Insider Proposes to Sell 6.09 Million in Common Stocks
Teva Pharmaceutical Industries Ltd. to Release Q4 and Full Year 2024 Financial Results on January 29, 2025
Teva Pharmaceutical Industries Options Spot-On: On December 20th, 113.39K Contracts Were Traded, With 981.61K Open Interest
US MOVERS & SHAKERS Dec 16-Dec 20, 2024
UBS Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Raises Target Price to $28
Teva Pharmaceutical Industries Options Spot-On: On December 18th, 95,900 Contracts Were Traded, With 952.86K Open Interest